Novel Substituted Tetrahydropyrrolooxazolones as RIPK1 Inhibitors
This patent discloses tetrahydropyrrolooxazolones as novel receptor-interacting protein kinase 1 (RIPK1) inhibitors as potential treatments for RIPK1-related diseases. It provides details in the synthesis of the tetrahydropyrrolooxazolones, pharmaceutical compositions, and therapeutic applications for RIPK1-related diseases.
Authors
- Steven H. Liang (ORCID: https://orcid.org/0000-0003-1413-6315)
- Jian Rong (ORCID: https://orcid.org/0000-0002-3960-1669)
Institutions
- Emory University (US)
- Union Hospital (CN)
Publication Details
- Journal
- ACS Medicinal Chemistry Letters
- Published
- 2026-04-21
- DOI
- https://doi.org/10.1021/acsmedchemlett.6c00188
- Primary Topic
- Ubiquitin and proteasome pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.00